Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lorcaserin

EISAI

Eisai given early approval for new oncology drug

Japanese firm’s thyroid cancer treatment Lenvimaset to be a blockbuster

- PMLiVE

CHMP thumbs up for Novo’s obesity drug Saxenda

Diabetes drug liraglutide on course for new indication in EU

- PMLiVE

Is obesity really a problem in Brazil?

Obesity is on the rise in low- and middle-income countries, particularly in urban settings

- PMLiVE

FDA approval for Novo Nordisk’s obesity shot

New formulation of diabetes drug Victoza will be marketed as Saxenda

- PMLiVE

Orexigen’s obesity pill Mysimba set for European approval

But sales of the treatment are only predicted to reach $200m by 2016

EISAI

Eisai establishes neuroscience unit in Belgium and Luxembourg

Follows the company's recent expansion in Australia

- PMLiVE

Eisai’s cancer cookbook wins CSR award

Around the Kitchen Table project see success at PMEA 2014

EISAI

Eisai opens first office in Australia

New Melbourne base to support marketing of Halaven and Fycompa

EISAI

Eisai “speechless” as G-BA denies price premium for Fycompa

But company has better news on cancer drug Halaven

- PMLiVE

Eisai backs competition to find star of epilepsy comic book

Teams up with Medikidz to educate young people about the condition

The pharma business environment in the US

Tighter regulations, more pricing controls and increased international competition will drive market improvements

- PMLiVE

Takeda’s obesity drug Contrave launches in US

Clears cardiovascular safety hurdle to be third new weight-loss drug in recent months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links